For years, GLP-1 receptor agonists occupied a narrow corner of the medical world. They were seen primarily as diabetes medications, tools for lowering blood sugar and managing A1c. Everything changed when clinical trials, real-world evidence, and patient outcomes revealed something far more profound: these medications are not just glucose-lowering agents but powerful drivers of metabolic healing across multiple organ systems. Today, drugs like semaglutide (Ozempic, Wegovy)  a